# Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen

> **NCT06680050** · PHASE2 · RECRUITING · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 21 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer NSCLC

## Interventions

- **DRUG:** Durvalumab (MEDI4736)
- **DRUG:** Ceralasertib
- **RADIATION:** radiotherapy

## Key facts

- **NCT ID:** NCT06680050
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-07
- **Primary completion:** 2028-06
- **Final completion:** 2029-01
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06680050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06680050, "Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06680050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*